返回
Prokidney Corp（PROK）价格
PROK 股价走势图
PROK 收益
Prokidney Corp
$2.29
5.04%
$0.1
收盘价：Jan 16, 16:00:00 GMT-5
$2.24
-2.18%
$-0.04
盘后：Jan 16, 20:00:00 GMT-5
关键数据
前收盘价
$2.18
开盘价
$2.21
当日区间
$2.16 - $2.31
52周范围
$0.46 - $7.13
交易量
1.5M
平均成交量
1.3M
每股收益（TTM）
-0.54
股息收益率
--
市值
$673.8M
什么是 PROK？
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The company went IPO on 2021-06-30. The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.